Tags

Type your tag names separated by a space and hit enter

Rimonabant: new data and emerging experience.
Curr Atheroscler Rep. 2008 Feb; 10(1):71-8.CA

Abstract

The endogenous cannabinoid system has been identified as playing a central role in the regulation of energy homeostasis, and its overactivity has been associated with obesity. Rimonabant is a selective endocannabinoid CB(1) receptor antagonist that has been shown to be an effective treatment for obesity and cardiometabolic risk factors. Studies comparing 20 mg/d of rimonabant with placebo show a placebo-subtracted weight loss between 6.3 and 6.9 kg at 1 year. In addition to the health benefits already associated with weight loss, rimonabant has shown additional improvements in lipid and glycemic cardiometabolic biomarkers such as low-density lipoprotein cholesterol, triglycerides, C-reactive protein, glucose, and adiponectin. The use of endocannabinoid antagonists such as rimonabant provides a promising therapeutic approach to the treatment of obesity and its associated cardiometabolic risks.

Authors+Show Affiliations

Comprehensive Weight Control Program, New York-Presbyterian Hospital, Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10065, USA. smw2004@med.cornell.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18366988

Citation

Wright, Suzanne M., et al. "Rimonabant: New Data and Emerging Experience." Current Atherosclerosis Reports, vol. 10, no. 1, 2008, pp. 71-8.
Wright SM, Dikkers C, Aronne LJ. Rimonabant: new data and emerging experience. Curr Atheroscler Rep. 2008;10(1):71-8.
Wright, S. M., Dikkers, C., & Aronne, L. J. (2008). Rimonabant: new data and emerging experience. Current Atherosclerosis Reports, 10(1), 71-8.
Wright SM, Dikkers C, Aronne LJ. Rimonabant: New Data and Emerging Experience. Curr Atheroscler Rep. 2008;10(1):71-8. PubMed PMID: 18366988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rimonabant: new data and emerging experience. AU - Wright,Suzanne M, AU - Dikkers,Carolien, AU - Aronne,Louis J, PY - 2008/3/28/pubmed PY - 2008/5/16/medline PY - 2008/3/28/entrez SP - 71 EP - 8 JF - Current atherosclerosis reports JO - Curr Atheroscler Rep VL - 10 IS - 1 N2 - The endogenous cannabinoid system has been identified as playing a central role in the regulation of energy homeostasis, and its overactivity has been associated with obesity. Rimonabant is a selective endocannabinoid CB(1) receptor antagonist that has been shown to be an effective treatment for obesity and cardiometabolic risk factors. Studies comparing 20 mg/d of rimonabant with placebo show a placebo-subtracted weight loss between 6.3 and 6.9 kg at 1 year. In addition to the health benefits already associated with weight loss, rimonabant has shown additional improvements in lipid and glycemic cardiometabolic biomarkers such as low-density lipoprotein cholesterol, triglycerides, C-reactive protein, glucose, and adiponectin. The use of endocannabinoid antagonists such as rimonabant provides a promising therapeutic approach to the treatment of obesity and its associated cardiometabolic risks. SN - 1534-6242 UR - https://www.unboundmedicine.com/medline/citation/18366988/Rimonabant:_new_data_and_emerging_experience_ L2 - https://medlineplus.gov/obesity.html DB - PRIME DP - Unbound Medicine ER -